ClinicalTrials.gg
CompletedNCT01085695Updated May 13, 2013

Study of E3810 for Healthy Japanese Male (Under Fasting Condition)

A Phase 1 interventional study of rabeprazole and rabeprazole in Healthy, sponsored by Eisai Co., Ltd.. Completed. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-05-13.

Sponsored by Eisai Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
20 Years to 40 Years
Sex
Male
01

Study summary

The purpose of this study is to assess the pharmacokinetics of rabeprazole under fasting condition.

Read the detailed description

The purpose of this study is to assess bioequivalence after single administration of the following 4 types of formulation: normal 10 mg rabeprazole tablet rabeprazole, and Type 1, Type 2, and Type 3 granule formulation containing rabeprazole 10 mg.

02

Conditions studied

  • Healthy

Keywords

  • Rabeprazole
  • Japan
  • healthy Japanese male
03

In context

Lead sponsor

Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects with homozygous or heterozygous extensive metabolizers of cytochrome P4502C19.

Exclusion criteria

Exclusion criteria:

Subjects with allergy

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    1

    Drug: rabeprazole

  • Experimental
    2

    Drug: rabeprazole

  • Experimental
    3

    Drug: rabeprazole

  • Active comparator
    4

    Drug: rabeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. The following pharmacokinetic parameters are calculated: maximum drug concentration (Cmax) in plasma; area under the plasma concentration time curve (AUC)

    Time frame: One day

Secondary outcomes

  1. Vital signs, clinical laboratory screens of blood and urine, adverse event monitoring, adverse drug reaction monitoring

    Time frame: 13 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2010
First posted
Mar 12, 2010
Start
Apr 2010
Primary completionActual
May 2010
CompletionActual
May 2010
Last update
May 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01085695
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Mar 12, 2010
Start date
Apr 2010
Primary completion
May 2010
Completion
May 2010
Last update
May 13, 2013

Study contacts

Kai Shibata
study director · Clinical Research Center, Eisai, Co., Ltd
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion